Edouard Philippe estime qu'il serait "absurde" de ne pas étudier une autorisation du cannabis thérapeutique France Info , 5 avril 2019 En déplacement dans la Creuse, qui envisage la création d'une filière de production, le Premier ministre s'est dit favorable "à expérimenter (...) de façon très encadrée". La France s'ouvrira-t-elle un jour à l'utilisation du cannabis thérapeutique ? Edouard Philippe a déclaré, vendredi 5 avril, qu'il serait "absurde" de s'interdire d'étudier cette possibilité. Le Premier ministre était en déplacement dans la Creuse, un département où la culture du cannabis à des fins médicales est envisagée comme un moyen de développer l'emploi et l'économie. "Il y a beaucoup de [...]
Lire la suiteThe Treatment of Cannabis Use Disorder Itai Danovitch, David A. Gorelick, Chapter,The Assessment and Treatment of Addiction, january 2019 Abstract: Worldwide, cannabis is the most commonly used illicit substance. Approximately 8-12% of persons who use cannabis will develop cannabis use disorder (CUD) at some point in their life. Several psychosocial treatment methods have shown efficacy in controlled clinical trials, including motivational enhancement therapy, cognitive behavioral therapy, and contingency management. While no pharmacotherapy has been established as broadly effective for CUD, gabapentin and N-acetylcysteine have shown efficacy in single controlled clinical trials, and a number of promising approaches are under study. This article reviews established [...]
Lire la suiteCannabis Use Disorder During the Perinatal Period Martha L. Velez, Chloe J. Jordan, and Lauren M. Jansson Chapter 17, in : I. D. Montoya, S. R. B. Weiss (eds.), Cannabis Use Disorders, 2019, © Springer Nature Switzerland AG 2019 177 https://doi.org/10.1007/978-3-319-90365-1_17 Introduction Cannabis use in the perinatal period has been increasing in recent years, coincident with increasing legalization in the USA for medical or recreational purposes [1]. Marijuana is the most commonly used illicit drug during pregnancy [2], and among some populations, it is used more frequently than tobacco [3, 4]. Although the prevalence of cannabis use during pregnancy is difficult to ascertain with accuracy, [...]
Lire la suitehttps://enseignements-2018.ehess.fr/2018/ue/2998// Études psychédéliques, approche historique Vincent Verroust, doctorant à l'EHESS ( CAK )Cet enseignant est référent pour cette UE S'il s'agit de l'enseignement principal d'un enseignant, le nom de celui-ci est indiqué en gras. Lundi de 18 h à 19 h 30 (MNHN, amphithéâtre Rouelle, 57 rue Cuvier, 75005 Paris (plan détaillé ici : https://drive.google.com/file/d/1h-oVy6oTh7UTMh84X-o448VhCCmBMp-M/view?usp=sharing), voir les dates dans le programme détaillé Cet atelier, ouvert aux étudiant-e-s, doctorant-e-s et chercheur-e-s, propose un programme de conférences portant sur le thème des substances dites « psychédéliques », selon terme inventé en 1956 par le psychiatre britannique Humphry Osmond. Il s’agit de proposer une étude historique [...]
Lire la suiteThe International Society for the Study of Drug Policy (ISSDP) is a society of scholars committed to advancing drug policy research. The 13th ISSDP conference The 13th ISSDP conference will be held in Paris, France on 22-24 May 2019. The conference will be hosted by Cermes3 at the Paris School of Economics. More information regarding the Conference Venue and how to get there. We look forward to seeing you in France! Alex Stevens, President, ISSDP Marie Jauffret-Roustide, Paris Conference Host Call for abstract is now closed. The results will be sent the 8th of March. Information regarding the Conference: Pratical information Register to the 13th ISSDP conference Keynote [...]
Lire la suiteSynthetic Cannabinoids and Synthetic Cannabinoid-Induced Psychotic Disorders (Chapitre 9) Papanti Duccio*,†, Schifano Fabrizio†, Orsolini Laura†,‡ *Drug Addiction Centre, Latisana, Italy †University of Hertfordshire, Hatfield, United Kingdom ‡Polyedra Research Group, Teramo, Italy The Complex Connection Between Cannabis and Schizophrenia. (Chapitre 9) http://dx.doi.org/10.1016/B978-0-12-804791-0.00009-4 © 2018 Elsevier Inc. All rights reserved. INTRODUCTION Both phytocannabinoids, the psychoactive compounds naturally present in the cannabis plant, and synthetic cannabinoids (SCs; also known as synthetic cannabimimetics) exert their effects through alteration of the endocannabinoid system (Szabo, 2014). There are at least 104 different phytocannabinoids in cannabis, and their combination contributes to the psychoactive effects of cannabis (ElSohly & Gul, 2014). In 1967, the United States [...]
Lire la suite